<DOC>
	<DOCNO>NCT02008513</DOCNO>
	<brief_summary>This follow-up study ass safety clinical activity continue AFFITOPE® AD02 vaccination patient Alzheimer 's disease . Patients , already participate AFF006 involve 27 study site Europe . Duration patient 's participation clinical trial 19 month .</brief_summary>
	<brief_title>Follow-up Study Assess Safety Clinical Activity Continued AFFITOPE® AD02 Vaccinations Patients Who Participated AFF006</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>patient participate AFF006+having receive 6 investigational medicinal product ( IMP ) injections+having complete visit Written inform consent Availability partner/caregiver Female patient childbearing potential eligible use medically accept contraceptive method . Scheduled elective hospitalization diagnostic workup allow inclusion clinical trial . Pregnant woman . Sexually active woman childbearing potential use medically accept birth control method unreliable contraception male subject . Participation active treatment phase another clinical trial except AFF006 within 3 month Visit 0 . History questionable compliance visit schedule ; patient expect complete clinical trial . Presence history allergy component vaccine , consider relevant investigator . Contraindication MRI image Presence and/or history immunodeficiency ( e.g. , HIV infection ) . Prior and/or current treatment experimental immunotherapeutics include Intravenous immunoglobulin ( IVIG ) , AD antibody therapy and/or vaccine AD except AD02 . Prior and/or current treatment immunosuppressive drug . Treatment benzodiazepines and/or nootropics administer high dos and/or newly start treatment . Treatment anticholinergic drug include Parkinson treatment , antidepressant ( tricyclic ) , neuroleptic anticholinergic property , certain bladder relaxant , anticholinergic drug use lung disease .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>AFFITOPE® AD02</keyword>
	<keyword>Alzheimer Disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>Brain Disease</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Tauopathies</keyword>
	<keyword>Neurodegenerative Diseases</keyword>
	<keyword>Mental Disorders</keyword>
</DOC>